Clinical Trial Update: Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Vicriviroc's effect on HIV RNA levels in cerebrospinal fluid in HIV infections; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Vicriviroc (MK-7690)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infections | Phase 1 | Status: COMPLETED